INTRODUCTION
Multiple sclerosis (MS) is a relatively common disease affecting an estimated 2.5 million individuals worldwide. Onset of MS will occur before the age of 18 years in~5% of cases, 1 with a childhood onset incidence of about 0.5 per 100 000 person-years in western countries. 1, 2 These numbers translate to about 4000 new cases of pediatric onset MS in the United States and European Union per annum. Although children often have a favorable disease course in the short term, patients with pediatric onset will reach disability milestones at an earlier age, reaching expanded disability status scale (EDSS) 3 scores 4, 6 and 7 on average 10 years earlier. 1, 4 The consequences of pediatric MS are particularly grave, as it occurs during a period of brain development and during the key formative years of education. Cognitive impairment is common, even with disease modifying therapy and has been observed iñ 30% of patients. 5, 6 Such deficits will have an adverse effect on academic performance, with life-long consequences beyond physical disability.
To date, there have been no randomized clinical trials of disease modifying drugs for pediatric MS. Safety and tolerability of currently available therapies have been evaluated in several open studies, containing some data on efficacy. Standard treatment of pediatric MS includes interferon-β and glatiramer acetate. 7, 8 However, many patients will continue to have relapses and increasing disability despite first-line treatment. Insufficient data are available on safety and efficacy of second or third line treatments in this group.
Autologous hematopoietic transplantation (aHSCT) has been used as a treatment of MS for more than 20 years. 9 The goal of this procedure is to ablate the erroneous immune system, using hematopoietic stem cells as a supportive blood product to ensure and hasten recovery. Several open studies and case series and one small randomized study (The Autologous Haematopoietic Stem Cell Transplantation trial in MS, ASTIMS) suggest that this treatment may lead to improvement in disability and long-term stability in adults. [10] [11] [12] [13] [14] [15] [16] Such an approach is particularly appealing in children, as it can lead to nearcomplete elimination of inflammation in the brain, which may provide favorable conditions for normal brain development. Furthermore, it is a one-time treatment and most patients do not require subsequent treatment with disease-modifying drugs minimizing the exposure to sometimes dangerous drugs with adverse effects negatively impacting quality of life during formative years.
The purpose of this study was to investigate efficacy and adverse events in children under 18 years treated with aHSCT for MS using data from the European Society for Blood and Marrow Transplantation (EBMT) registry.
MATERIALS AND METHODS
This study was designed as a retrospective multicenter study analyzing all available data in the EBMT registry on 1 January 2016 and additional information requested with a specifically designed questionnaire. All EBMT centers were invited to participate and report data from patients diagnosed with MS who had been treated with aHSCT before 18 years of age. Patients who had been treated with aHSCT primarily for a disease other than MS were excluded.
The primary endpoint was initially set to PFS at 5 years after transplant, which was subsequently changed to PFS at 3 years (reflecting a slightly lower median follow-up time than expected). Progression was defined as an increase in EDSS score with at least 1 point from baseline, sustained between two follow-up visits separated in time by no less than 6 months, for patients with baseline EDSS ⩽ 5 and an increase in EDSS score with at least 0.5 points from baseline for patients with baseline EDSS45. The baseline was defined as the last assessment before the mobilization part of the procedure. Similarly, EDSS improvement was defined as a decrease of the EDSS score, sustained between two follow-up visits separated in time by no less than 6 months, by at least 1 point from baseline if the EDSS was in the range of 0-5.5 and with 0.5 points if the EDSS was ⩾ 6.
Magnetic resonance imaging (MRI) event-free survival, relapse-free survival, no evidence of disease activity, annualized relapse rate, EDSS improvement and overall mortality were secondary endpoints. An MRI event was defined as appearance of any T2 lesion 43 mm in the brain or spinal cord present on the latest MRI scan, but not present on the baseline scan. A clinical relapse was defined as a period of acute worsening of neurological function lasting ⩾ 24 h not attributable to an external cause such as increased body temperature or acute infection. No evidence of disease activity was defined as no progression of disability, absence of new T2 lesions on MRI and no new relapses. 17, 18 The annualized relapse rate was calculated by counting the number of relapses occurring in a given time period and dividing it by the length of that time period.
The number of patients treated in the intensive care unit and the number of patients with culture negative fever and bacteremia with fever within 100 days from the start of the conditioning regimen was recorded. We also assessed the number of days from aHSCT to engraftment. Engraftment was defined as ANC 40.5. Furthermore, any subsequent development of malignancies and other autoimmune disease throughout the entire follow-up period was recorded.
RESULTS

Study cohort
Twenty-two patients treated with aHSCT for MS at seven different centers could be identified in the EBMT registry. One patient was treated at a center that did not respond to communication despite several reminders. The remaining 21 patients were included in the data set. Patient characteristics are summarized in Table 1 and data on individual patients are presented in Table 2 . All patients had previously been treated with at least one disease-modifying drug, 11 had been treated with at least two disease-modifying drugs and four had tried more than two previous treatments. Previous treatments were interferon-β, n = 20; intravenous IgG, n = 4; cyclophosphamide, n = 3; glatiramer acetate, n = 3; natalizumab, n = 3; mitoxantrone, n = 2; and azathioprine n = 1. The median follow-up time after aHSCT was 2.8 years (range 0.1-13.2 years).
Procedures
Peripheral hematopoietic stem cells were mobilized with cyclophosphamide (1.5-4 g/m 2 ) and filgrastim (5-45 μg/kg). The graft from two patients was CD34+ selected, otherwise no ex vivo graft manipulation was performed. Two different conditioning protocols were used. Eight patients were treated with the BEAM protocol (BCNU 300 mg/m 2 , etoposide 800 mg/m 2 , cytosinearabinoside 800 mg/m 2 and melphalan 140 mg/m 2 ) and 13 received a cyclophosphamide based conditioning (200 mg/kg). Twenty patients received ATG (rATG 5-10 mg/kg, n = 10; rATG 45 mg/kg, n = 1; and hATG 40 mg/kg, n = 9). All patients received at least 2 × 10 6 /kg CD34 + hematopoietic stem cells (mean 5.7 × 10 6 ± 3.6 × 10 6 ). Mean time to engraftment was 11 ± 2.0 days, with no statistically significant difference between the BEAM and cyclophosphamide-based regimen.
Primary endpoint
No patient experienced an EDSS increase post HSCT above baseline. Accordingly, PFS at 3 years after transplant was 100%.
Secondary endpoints
Two patients experienced a clinical relapse post HSCT, both occurring about 2 years after the procedure. Both patients also had simultaneously appearing gadolinium-enhancing lesions. These patients were classified as secondary progressive MS (SPMS) patients. One further patient with relapsing-remitting MS had subclinical disease with new T2-lesions and gadoliniumenhancing lesions in the absence of relapses. Unfortunately, one patient did not have follow-up MRI and data were missing for two additional patients. As a consequence, it was difficult to assess freedom from disease activity, but evidence of post-HSCT disease activity was present in only 3 out of 18 evaluable patients. Notably, four patients had follow-up for 10 years or more, with no records of recurring disease activity.
The post-HSCT annualized relapse rate was 0.022. Sixteen patients improved in EDSS, the median EDSS at last follow-up was 2.5 and the median improvement in the EDSS was 2.0 (range 0-8). relapsing-remitting MS patients improved slightly more than SPMS patients (median improvement 2.0 vs 1.5), but the low number of patients does not permit a statistical analysis.
All patients were alive at last follow-up. One patient required intensive care due to Pseudomonas aeruginosa sepsis, 2 additional patients suffered from fever with culture verified bacteremia and 12 patients experienced culture negative fever during inpatient care. One patient had a subclinical CMV reactivation with 2500 CMV copies/mL, which was treated with ganciklovir. One patient, who received a CD34-selected graft, got an EBV reactivation approximately 2 months after transplant with a maximum number of EBV copies of 11 499/mL. The patient was treated with foscarnet, after which the EBV infection was cleared and the patient made a full recovery. No patient developed invasive fungal Abbreviations: ARR = annualized relapse rate; BEAM = BCNU, etoposide, cytosine-arabinoside and melphalan; Cy = cyclophosphamide; EDSS = expanded disability status scale; MS = multiple sclerosis; RRMS = relapsing-remitting MS; SPMS = secondary progressive MS. The conditioning regimen was based on either Cy or a combination of four cytotoxic agents, that is, BEAM.
HSCT for MS in children J Burman et al infection. One patient experienced a gastrointestinal bleed and developed signs of mild disseminated intravasal coagulation. One other patient developed hemichorea 1 week after the conditioning regimen had been completed. This was likely to be due to an MS relapse, with a gadolinium-enhancing lesion in the contralateral basal ganglia on MRI scan. It resolved spontaneously within weeks and at 3 months follow-up no chorea was present. Onset of new autoimmune disease after aHSCT was recorded in two patients, one who developed autoimmune thyroiditis and one Crohn's disease. No malignancies were reported.
Post-HSCT treatment
Six patients received treatment after aHSCT. One patient who developed gadolinium-enhancing lesions after aHSCT was treated with rituximab. Another patient was treated with intravenous IgG according to a pre-planned protocol. Furthermore, four patients treated at one center received adjuvant therapy with ex vivo expanded T-regulatory cells 51-786 days after aHSCT. In brief, 40 cc blood were drawn and T-regulatory cells were expanded in cell culture for 5-8 days. A mean number of 6.44 ± 1.3 × 10 7
T-regulatory cells were infused subcutaneously. No serious adverse events were recorded for this procedure. One of these patients received adjuvant Treg therapy before a subsequent relapse and another following a relapse. Further evaluation of the response to post-HSCT treatment in these patients is pending.
DISCUSSION
This is the first report of treatment with aHSCT for MS in children.
The procedure was generally well tolerated and only one patient experienced unexpected serious adverse events. Seventy-six percent of patients improved in EDSS and no patient deteriorated from baseline. Data on safety and efficacy of aHSCT for MS in adults have recently been reported in several case series and nationwide surveys. [10] [11] [12] [13] [14] 16 Treatment-related mortality was 4.2% in a Canadian phase II trial with a high-intensity conditioning regimen 16 and 2.7% in an Italian study describing outcome of 73 MS patients treated with an intermediate-intensity conditioning regimen (BEAM). 10 In other reports containing in total 322 patients treated with low-and intermediate-intensity regimens, there was no treatment-related mortality. [11] [12] [13] [14] In the long term, well-known side effects are herpes zoster reactivation, which has been reported in 2.6-15% of patients, 10, 12, 14 and thyroid disease with a prevalence of 4.0-8.4% post HSCT. 10, 12, 14 In the present study, there was no treatment-related mortality, no case of herpes zoster and one case of thyroid disease. The low number of patients in this study does not enable a reliable estimation of treatment related adverse events or treatment-related mortality, but it is nevertheless reassuring that there seems to be no excess of serious adverse events in children in comparison with adults.
The impact of aHSCT on growth, development and later fertility is of major concern in any transplant performed in children and young adults. These aspects were not assessed systematically in this study, but should be taken in consideration, especially when treating pre-pubertal patients. The use of low intensity conditioning regimens may limit the negative long term effects of cytotoxic agents. 19 From this perspective, a cyclophosphamide based conditioning regimen may therefore be preferable to more intensive regimens, such as BEAM. To improve the state of current knowledge, patients should be screened for late effects according to current guidelines. 20 aHSCT for MS may be more efficacious in children than in adults. PFS in the present study was 100% in comparison with 66-91% at 3-5 years after aHSCT in adults.
10-14 EDSS improvement was also seen to a substantially higher degree than the 50% reported from one study.
14 aHSCT also compares somewhat favorably with natalizumab treatment in children with MS, where 46% of patients improved at least 1 point in the EDSS and disease-free survival was 58% in one large case series. 21 In a smaller case series of rituximab-treated children with low-grade disability, median EDSS improved with 0.5 points and disease-free survival was 57%. 22 About half of the patients included in this study were diagnosed with SPMS, which is considered rare in children. This may be a classification error but could also be due to an enrichment of the most severe cases considered for this procedure. Nevertheless, most of the patients diagnosed with SPMS had gadolinium-enhancing lesions and relapses, suggesting an inflammatory phenotype, consistent with active SPMS in the Lublin classification. 23 There are several limitations to this study. First, the number of patients is relatively small, restricting any firm conclusions. Second, although data were entered prospectively into the EBMT registry for the most part, some data points were missing and had to be retrospectively gathered from participating centers. Despite these efforts some data points could not be retrieved for the final analysis. Third, although more than 10 years of follow-up data were available for some patients, the majority of patients were followed for less than 3 years. Fourth, some data of particular interest in a pediatric population, such as growth and development were not collected. Finally, although widely used, the EDSS may not be the most appropriate marker to assess treatment response in children, as they do not typically accrue physical disability early in the disease, and are more likely to suffer from cognitive symptoms or fatigue, which are not adequately measured by this scale.
Although often seen as benign in the short term, pediatric onset MS is a particularly severe form of MS with impact on development, acquisition of skills and education, necessary for a normal adult life. Treatment of children with MS should therefore aim at early disease control and the threshold for treatment escalation should be low. In 2012, the International Pediatric Multiple Sclerosis Study Group put forth guidelines for assessment of treatment efficacy. In the guidelines inadequate treatment is defined by either an increase or no reduction in relapse rate, new T2 or contrast enhancing lesions on MRI, or two or more confirmed clinical exacerbations within a 12-month period or less. 24 aHSCT is a promising alternative for children failing standard therapy, with the advantages of immediate disease control and functional improvement in a majority of patients. Furthermore, this one time procedure offers the advantage of avoiding adverse events associated with the continuous administration of disease-modifying drugs, which could affect school performance and have a negative impact on quality of life. On the downside, aHSCT is associated with risk of serious adverse events, such as potentially dangerous infections, secondary autoimmunity and decreased fertility. A more precise estimation of such risks should be subject to further study; meanwhile, we advocate that this procedure be performed at experienced centers only.
CONCLUSIONS aHSCT for pediatric MS appears to be safe and a large majority of patients will be stable with no signs of disease activity for a prolonged time after the procedure. A reasonable approach is to try other less toxic treatments first and reserve this treatment for patients with breakthrough disease.
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